NasdaqGM - Nasdaq Real Time Price USD
Arcturus Therapeutics Holdings Inc. (ARCT)
12.65
+0.48
+(3.94%)
At close: April 23 at 4:00:00 PM EDT
12.62
-0.03
(-0.24%)
Pre-Market: 9:20:35 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 8 |
| Avg. Estimate | -1.1 | -1.31 | -5.05 | -3.94 |
| Low Estimate | -2.1 | -2.16 | -8.79 | -5.98 |
| High Estimate | 0.19 | -0.74 | -2.36 | -1.36 |
| Year Ago EPS | -1 | -0.64 | -3 | -5.05 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 11 | 10 |
| Avg. Estimate | 23.14M | 18.42M | 96.43M | 142.65M |
| Low Estimate | -- | -- | -- | 29.52M |
| High Estimate | 57.25M | 29.7M | 166.31M | 279.39M |
| Year Ago Sales | 38.01M | 49.86M | 152.31M | 96.43M |
| Sales Growth (year/est) | -39.12% | -63.05% | -36.69% | 47.94% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.14 | -1.57 | -1.02 | -0.49 |
| EPS Actual | -1 | -0.64 | -0.26 | -1.11 |
| Difference | 0.14 | 0.93 | 0.76 | -0.62 |
| Surprise % | 12.59% | 59.23% | 74.60% | -124.56% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.1 | -1.31 | -5.05 | -3.94 |
| 7 Days Ago | -1 | -1.24 | -4.78 | -3.8 |
| 30 Days Ago | -1 | -1.24 | -4.78 | -3.8 |
| 60 Days Ago | -0.28 | 0.09 | -1.74 | 0.33 |
| 90 Days Ago | -0.27 | 0.5 | -1.48 | 0.76 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | 2 | 2 | 1 | 1 |
| Down Last 30 Days | 3 | 3 | 3 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ARCT | -9.87% | -104.49% | -68.27% | 21.91% |
| S&P 500 | 6.85% | 4.67% | 8.41% | 14.16% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/10/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/10/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/7/2025 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/7/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/7/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/18/2025 |
Related Tickers
EDIT Editas Medicine, Inc.
1.5600
0.00%
PHAT Phathom Pharmaceuticals, Inc.
4.0200
+1.52%
VIR Vir Biotechnology, Inc.
5.97
+2.93%
IMVT Immunovant, Inc.
14.45
+1.40%
NTLA Intellia Therapeutics, Inc.
8.09
-2.65%
DNLI Denali Therapeutics Inc.
14.87
+1.85%
RARE Ultragenyx Pharmaceutical Inc.
37.31
+3.90%
CAPR Capricor Therapeutics, Inc.
13.15
-5.33%
CVAC CureVac N.V.
3.1700
-0.63%
OCUL Ocular Therapeutix, Inc.
7.85
-0.76%